Publications

Markowitz GJ, Ban Y, Tavarez DA, Yoffe L, Podaza E, He Y, Martin MT, Crowley MJP, Sandoval TA, Gao D et al..  2023.  Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve checkpoint blockade.. Res Sq.

Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.

Cheong J-G, Ravishankar A, Sharma S, Parkhurst CN, Grassmann SA, Wingert CK, Laurent P, Ma S, Paddock L, Miranda IC et al..  2023.  Epigenetic memory of coronavirus infection in innate immune cells and their progenitors.. Cell. 186(18):3882-3902.e24.

Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S et al..  2023.  Evolution of structural rearrangements in prostate cancer intracranial metastases.. NPJ Precis Oncol. 7(1):91.

Ladewig MS, Jacobsen JOB, Wagner AH, Danis D, Kassaby BEl, Gargano M, Groza T, Baudis M, Steinhaus R, Seelow D et al..  2023.  GA4GH Phenopackets: A Practical Introduction.. Adv Genet (Hoboken). 4(1):2200016.

Kulm S, Kaidi AC, Kolin D, Langhans MT, Bostrom MP, Elemento O, Shen TS.  2023.  Genetic Risk Factors for End-Stage Hip Osteoarthritis Treated With Total Hip Arthroplasty: A Genome-wide Association Study.. J Arthroplasty. 38(10):2149-2153.e1.

Jessurun J, Orr C, McNulty SN, Hagen CE, Alnajar H, Wilkes D, Kudman S, Assaad MAl, Dorsaint P, Ohara K et al..  2023.  GLI1 -Rearranged Enteric Tumor : Expanding the Spectrum of Gastrointestinal Neoplasms With GLI1 Gene Fusions.. Am J Surg Pathol. 47(1):65-73.

Nazha A, Elemento O, McWeeney S, Miles M, Haferlach T.  2023.  How I read an article that uses machine learning methods.. Blood Adv. 7(16):4550-4554.

Van Emmenis L, Ku S-Y, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V et al..  2023.  The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.. Cancer Res Commun. 3(8):1447-1459.

Bovonratwet P, Kulm S, Kolin DA, Song J, Morse KW, Cunningham ME, Albert TJ, Sandhu HS, Kim HJo, Iyer S et al..  2023.  Identification of Novel Genetic Markers for the Risk of Spinal Pathologies: A Genome-Wide Association Study of 2 Biobanks.. J Bone Joint Surg Am. 105(11):830-838.

Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed AG, Bareja R, Alnajar H, Eng KWha, Conteduca V, Sboner A et al..  2023.  Immunogenomic Landscape of Neuroendocrine Prostate Cancer.. Clin Cancer Res. 29(15):2933-2943.

Assaad MAl, Gundem G, Liechty B, Sboner A, Medina J, Papaemmanuil E, Sternberg CN, Marks A, Souweidane MM, Greenfield JP et al..  2023.  The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer.. Cold Spring Harb Mol Case Stud. 9(4)

Noch EK, Palma LN, Yim I, Bullen N, Qiu Y, Ravichandran H, Kim J, Rendeiro A, Davis MB, Elemento O et al..  2023.  Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.. Neuro Oncol. 25(12):2165-2176.

Bakht MK, Yamada Y, Ku S-Y, Venkadakrishnan VBalaji, Korsen JA, Kalidindi TM, Mizuno K, Ahn SHye, Seo J-H, Garcia MMica et al..  2023.  Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.. Nat Cancer. 4(5):699-715.

Setton J, Hadi K, Choo Z-N, Kuchin KS, Tian H, Paula ADa Cruz, Rosiene J, Selenica P, Behr J, Yao X et al..  2023.  Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.. Nature. 621(7977):129-137.

Hegewisch-Solloa E, Melsen JE, Ravichandran H, Rendeiro AF, Freud AG, Mundy-Bosse B, Melms JC, Eisman SE, Izar B, Grunstein E et al..  2023.  Mapping human natural killer cell development in pediatric tonsil by imaging mass cytometry and high-resolution microscopy.. bioRxiv.

Huang SH, Sartorello G, Shen P-T, Xu C, Elemento O, Shvets G.  2023.  Metasurface-enhanced infrared spectroscopy in multiwell format for real-time assaying of live cells.. Lab Chip. 23(9):2228-2240.

Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, Maclachlan KH, Eng KWha, Uppal M, He F et al..  2023.  Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells.. Blood Cancer Discov. 4(3):208-227.

Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.. Blood. 141(18):2194-2205.

Scarpa JR, Elemento O.  2023.  Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review.. Br J Anaesth. 131(1):26-36.

Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, Barisic D, Papin A, Hoehn KB, Kots E et al..  2023.   mutation yields supercompetitive B cells primed for malignant transformation.. Science. 379(6629):eabj7412.

Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2023.  Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 14(1):8435.

Barnes J, Brendel M, Gao VR, Rajendran S, Kim J, Li Q, Malmsten JE, Sierra JT, Zisimopoulos P, Sigaras A et al..  2023.  A non-invasive artificial intelligence approach for the prediction of human blastocyst ploidy: a retrospective model development and validation study.. Lancet Digit Health. 5(1):e28-e40.

Bhardwaj P, Iyengar NM, Zahid H, Carter KM, Byun DJun, Choi MHo, Sun Q, Savenkov O, Louka C, Liu C et al..  2023.  Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in .. Sci Transl Med. 15(684):eade1857.

Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK et al..  2023.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. bioRxiv.